Celcuity (FRA:7VR) Issuance of Debt: €189.78 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7VR Celcuity Inc FRA:7VR
18 GF Score
Price €93.50
! 2 Warning Signs
View Full Analysis

What is Celcuity Issuance of Debt?

Celcuity FRA:7VR 18 Issuance of Debt is €189.78 Mil as of Mar. 2026. GuruFocus rates FRA:7VR with a GF Score™ of 18/100. The stock has 2 warning signs investors should review.

Celcuity's Issuance of Debt for the three months ended in Mar. 2026 was €0.00 Mil.

Celcuity's Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was €189.78 Mil.

Celcuity Issuance of Debt Related Terms

Celcuity Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Celcuity's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celcuity Issuance of Debt Chart

Celcuity Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.70 18.42 0.00 56.56 190.23

Celcuity Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 190.19 -0.41 0.00
FRA:7VR
18GF Score
Celcuity Inc FRA:7VR
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celcuity Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €189.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of €189.78 Mil mean?
Celcuity (FRA:7VR) has a Issuance of Debt of €189.78 Mil as of Mar. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Celcuity and its competitors.
Is Celcuity's Issuance of Debt too high?
Celcuity's current Issuance of Debt is €189.78 Mil. Overall, Celcuity has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Celcuity's Issuance of Debt compare to ERAS and TNGX?
Celcuity's Issuance of Debt of €189.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Celcuity and its competitors. Celcuity's current Issuance of Debt is €189.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celcuity stock overvalued right now?
Celcuity (FRA:7VR) has a current Issuance of Debt of €189.78 Mil. The current Issuance of Debt is €189.78 Mil. Celcuity's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Celcuity (FRA:7VR), the current Issuance of Debt is €189.78 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Celcuity Business Description

Other Exchanges CELC:USA
Address 16305 36th Avenue North, Suite 100, Minneapolis, MN, USA, 55446
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
18GF Score

Get the complete analysis for FRA:7VR

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€93.50
Price